Alembic Pharmaceuticals Reports First Prescription Sale of Pivya(pivmecillinam) Following US Commercial Launch

Ahmedabad, March 9: Alembic Pharmaceuticals Limited (“Alembic”) today announced the first prescription-based sale of Pivya (pivmecillinam) tablets, an oral prescription antibiotic, following its recent commercial launch in the United States of America (US). Pivya® is Alembic’s first branded pharmaceutical product in the US and is being marketed through Alembic Therapeutics LLC, a step-down wholly owned…

Read More

Alembic Pharmaceuticals Limited announces USFDA Final Approval for Lamotrigine Orally Disintegrating Tablets USP, 25 mg, 50 mg, 100 mg and 200 mg.

Ahmedabad, February 27th: Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Lamotrigine Orally Disintegrating Tablets USP, 25 mg, 50 mg, 100 mg and 200 mg. The approved ANDA is therapeutically equivalent to the reference listed drug…

Read More

Alembic Pharmaceuticals Limited announces USFDA Final Approval for Loteprednol Etabonate and Tobramycin Ophthalmic Suspension.

Ahmedabad  11th, December: Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Loteprednol Etabonate and Tobramycin Ophthalmic Suspension, 0.5%/0.3% (5 mL and 10 mL). The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Zylet…

Read More

Alembic Pharmaceuticals Limited announces USFDA Final Approval for Diltiazem Hydrochloride Tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg

AHMEDABAD,17TH November: Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Diltiazem Hydrochloride Tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg. The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Cardizem…

Read More

Alembic Pharmaceuticals Limited announces USFDA Final Approval Dexlansoprazole Delayed-Release Capsules, 30 mg and 60 mg

AHMEDABAD, November 14th: Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Dexlansoprazole Delayed-Release Capsules, 30 mg and 60 mg. The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Dexilant Delayed-Release Capsules, 30 mg…

Read More

Alembic Pharmaceuticals Limited announces USFDA Final Approval for Sumatriptan Injection USP

AHMEDABAD, 11THNovember: Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Sumatriptan Injection USP, 4 mg/0.5 mL and 6 mg/0.5 mL, Single-Dose Autoinjector System. The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Imitrex…

Read More

Alembic Pharmaceuticals and Amlan International launch MinerTox-Z and MinerTox-A

AHMEDABAD, 08 October: Alembic Pharmaceuticals Ltd., through a strategic agreement with Amlan International, today announced the India launch of MinerTox-Z and MinerTox-A, feed additive solutions developed to protect poultry against toxins and enhance farm productivity. The introduction of these products represents an important step in addressing one of the poultry industry’s most pressing challenges—losses caused…

Read More

Stocks in News: INSECTICIDES, ONGC, NBCC, NACL, BAJAJHF, RIL, BOSCH, BOB, TORRENTPHARMA, ALEMBIC PHARMA

MUMBAI, 4 JULY:   Insecticides India: CRISIL upgrades long-term credit rating from ‘CRISIL A/Stable’ to ‘CRISIL A+/Stable’.  (Positive) ONGC: Company & Mitsui O.S.K. Lines signed a Heads of Agreement on July 3, 2025, to build & operate two Very Large Ethane Carriers. (Positive) Indian Energy Exchange: Company Reports 15% YoY Growth in Power Trade Volume…

Read More